Phase III Survival Benefit Boosts Imbruvica’s Profile Ahead Of FDA’s CLL Decision
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
RESONATE study is halted after Pharmacyclics/Janssen’s Imbruvica shows a survival benefit as a monotherapy compared to GlaxoSmithKline’s Arzerra. Analysts expect results will pave way for off-label use ahead of FDA’s approval in CLL, though a delay for official clearance is possible.